Drug · CHEMBL4297828
ADEBRELIMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ADEBRELIMAB. Drugs and targets, record CHEMBL4297828. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL4297828
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Programmed cell death 1 ligand 1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/29126 |
Source ChEMBL
Diseases52
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| small cell lung carcinoma | Phase 3 | ClinicalTrials.gov | 44 | 44 | https://conductscience.org/library/drugs?q=MONDO_0008433 |
| non-small cell lung carcinoma | Phase 3 | ClinicalTrials.gov | 33 | 33 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| breast cancer | Phase 3 | ClinicalTrials.gov | 23 | 23 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| esophageal squamous cell carcinoma | Phase 2 | ClinicalTrials.gov | 22 | 22 | https://conductscience.org/library/drugs?q=MONDO_0005580 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 15 | 15 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| hepatocellular carcinoma | Phase 3 | ClinicalTrials.gov | 15 | 15 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| malignant pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| cancer | Phase 2 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0004992 |
| colorectal cancer | Phase 3 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
1 to 10 of 52Source Open Targets
See all 52 diseasesTrials270
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 9 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT06336707 | HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors | Phase 1 | 1,048 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT06350006 | SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor | Phase 1 | 924 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT06703177 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | Phase 1/2 | 876 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT07522151 | Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer | Phase 3 | 874 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT06879145 | Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) | Phase 2/3 | 840 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | Phase 1 | 762 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT07168200 | A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer | Phase 3 | 720 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | Phase 2 | 716 | shr-1316 | Its name | ClinicalTrials.gov | |
| NCT06332170 | ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | Phase 1 | 610 | adebrelimab | Its name | ClinicalTrials.gov | |
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) | Phase 3 | 604 | adebrelimab | Its name | ClinicalTrials.gov |
1 to 10 of 270
See all 270 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials53
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL4297828
GET https://conductscience.org/api/drugs/v1/CHEMBL4297828/diseases?page=2